Hidradenitis Suppurativa Treatment Market

Key data points: Market size in 2027 = $943 million and 2035 = $1310 million, growth forecast = 4.2% annually for the next 8 years. Scroll below to get more insights. This market report covers trends, opportunities and forecasts in hidradenitis suppurativa treatment market to 2035 by type (medications, surgery, and others), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World) Hidradenitis Suppurativa Treatment Market The future of the global hidradenitis suppurativa treatment market looks promising with opportunities in the hospital and clinic markets. The global hidradenitis suppurativa treatment market is expected to reach an estimated $1310 million by 2035 from $943 million in 2027 with a CAGR of 4.2% from 2027 to 2035. The major drivers for this market are the increasing prevalence of hidradenitis suppurativa, the rising demand for advanced treatment options, and the growing awareness of chronic skin conditions. • Lucintel forecasts that, within the type category, medications is expected to witness higher growth over the forecast period due to pharmacological management is becoming increasingly popular over surgery. • Within the application category, clinics is expected to witness higher growth over the forecast period due to the diagnosis and treatment of skin conditions are increasing at specialized clinics. • In terms of regions, APAC is expected to witness the highest growth over the forecast period due to more people are becoming aware of skin conditions and have better access to treatments. Gain valuable insights for your business decisions with our comprehensive 150+ page report. Sample figures with some insights are shown below. Emerging Trends in Hidradenitis Suppurativa Treatment Market The human treatment market for hidradenitis suppurativa (HS) is transitioning from the reliance on episodic antibiotic treatment to more continuous treatment. From 2025 to 2027, the use of immunologic therapies (i.e., biologics) along with specialized diagnosis and treatment by dermatologists is anticipated to improve and positively impact the HS treatment market. Lucintel is also projecting that the treatment of moderate-to-severe HS will experience greater demand in comparison to the treatment of mild HS. • Biologics: The U.S. Food and Drug Administration (FDA) approvals of both Secukinumab and Bimekizumab in 2020 provided two additional biologic options for HS. Similarly, the Phase 3 HS Clinical Study of Povorcitinib is expected to provide additional treatment options for HS. • Earlier Diagnosis: HS is often misdiagnosed or takes a significant amount of time to diagnose. A variety of digital resources are expected to be developed and/or implemented during 2025-2027 to provide dermatologic health care professionals with education on HS and other resources to assist them in performing HS diagnosis and evaluation. • Personalized Treatment: There are a growing number of research studies that indicate HS is related to and/or influenced by other conditions such as metabolic syndrome. • Integrated Care: Emphasis is on integrating specialty care (i.e., dermatology, surgery, and wound care) with behavioural health for patients with Hurley stage II and III lesions. Development of multidisciplinary clinics will enable better integration of care and improve value for patients. • Patient-centred Delivery: There is an increased focus on incorporating patient self-injection, use of tele dermatology, and remote patient monitoring, as well as collecting patient-reported outcomes, in both clinical and commercial research. Better delivery methods will improve adherence and allow patients to be served outside of major medical centres. The ability to improve patient outcomes through improved methods of delivery and integration of concurrent care (i.e., specialty care, primary care, and behavioural health) will assist companies in capturing a larger share of the market. Access continues to be the largest limitation in the market. Recent Developments in the Hidradenitis Suppurativa Treatment Market The field of Hidradenitis suppurativa (HS) treatment is expected to become more competitive, with biologics and other therapies expected to be commercialized in the upcoming years and an anticipated increase in the rate of diagnosis. In the 2025-2027 period, the HS treatment landscape is expected to change based on the results of clinical trials and the expansion of indications by pharmaceutical payers. It is expected that by 2027, the HS market will be larger and more competitive, with greater emphasis on the entire range of HS treatment options offered by pharmaceutical companies. • IL-17 Pathway Expansion: Novartis is expected to maintain its position in the HS market with its IL-17 inhibitor, secukinumab. In the clinical trials SUNSHINE and SUNRISE, which were initiated in June 2023 and which will continue through 2025, 1,084 HS patients will be enrolled. Following the completion of these studies, Novartis will be in a position to compete with other IL-17 inhibitors in the market. • Bimekizumab Commercialization: In October 2024, UCB received FDA approval to commercialize bimekizumab (an IL-17A/IL-17F inhibitor) for the treatment of HS. With clear skin as its end goal and lower dosing frequency compared to other HS treatments, bimekizumab is anticipated to be a threat to current market leaders. • Oral JAK Development: The only JAK-inhibitor to advance to Phase 3 clinical trials is Incyte’s psoriasis treatment, Povorcitinib (formerly: INCB13133). Early results showed an improvement in patients’ symptoms with greater reduction in inflammatory nodules with increased dosage. Currently, treatments for moderate forms of psoriasis include injectable biologics. The development of an oral treatment for moderate psoriasis would catalyze competition in the currently monopolized market. • Late-stage Pipeline Partnership: The results of 2024 Clinical Trials for IL-17A/F Nanobody, Sonelokimab, supported MoonLake’s decision to proceed with Phase 3 Studies. Recent achievements by the company demonstrated progress in molecular design of biologics, and supported the company’s goals of developing products with stronger capacities for ameliorating symptoms. • Diagnosis and Care Network Investment: June 2025 marked World Hidden Skinatosis Awareness Week. With numerous medical personnel participating in educational and promotional activities, the week’s events raised the public’s awareness of HS. Better public awareness and identification of HS will encourage earlier clinical referrals and diagnoses. This will increase the population of HS patients receiving appropriate medical intervention and care. Rising commercial interests will seek to strengthen the evidence of lesion reduction and minimize burdens and trade-offs in treatment. Ease of use will enhance preference for a treatment option. The treatment option most aligned with the values of the healthcare payer will appeal most to clinicians. Intensifying competition will grant greater access to treatment for patients suffering from HS. Strategic Growth Opportunities in the Hidradenitis Suppurativa Treatment Market Treatment of hidradenitis suppurativa is evolving to include use of biologics to achieve long-term disease control. The use of antibiotics to achieve disease control on a temporary basis is decreasing. The time period from 2024 to 2026 is expected to bring more published clinical studies and an increased number of patients, which will provide additional market opportunities. According to Lucintel, favorable strategies for the market in this time period will include diverse methods of product delivery and special pharmacy distribution. • Earlier Line Biologics: More effective treatments for hidradenitis suppurativa are expected to come to market in the next few years. In February 2025, the U.S. Food and Drug Administration approved three biologics for treatment of hidradenitis suppurativa. It is anticipated that treatments approved for use earlier in the disease process will promote disease control, improve the quality of life for patients, and allow for pricing above traditional biologics. • Digital Speciality Care: Specialty pharmacy distribution and advanced digital technologies will play a key role in improving access to care and coordination of remote follow-up for symptom control. A digital specialty care pathway will allow for improved case identification and improved continuity of care during the treatment process. • Emerging Market Access: Biologics for hidradenitis suppurativa will be reimbursed in a number of developing countries, thereby creating new market opportunities beyond North America and Europe. In March 2025, the population of India was estimated to be over 1.4 billion. Improved treatment processes and special care distribution will promote treatment adherence and control. • Personalized Treatment Services: Differentiation is crucial in the competitive biologics market. Products must incorporate severity-based frameworks and biomarker testing. In April 2025, over 20 interventional HS clinical studies were listed on ClinicalTrials.gov. How the evidence changes practice will impact reimbursement. Products influenced by these criteria are expected to be beneficial and warranted. • Comorbidity Focused Product: The existence of comorbidities extends the market potential of lesion-targeted products. Approximately 1.3 billion (37% of the world's population) were obese in 2025. The long-term success of therapies targeted at obesity and other comorbidities may lead to the adoption of these products by multidisciplinary teams. Revenue can be attributed to the clinical differentiation of biologics offered, rather than biologics alone. In the next 5 years, partnerships with payers and dermatologists will foster the creation of new diagnostic and evidence-based services. These services, coupled with proper localization and manufacturing, will increase the market potential. Hidradenitis Suppurativa Treatment Market Drivers and Challenges According to Lucintel, the hidradenitis suppurativa (HS) treatment market will benefit from increased awareness and improved diagnosis of the condition, innovation in the biologics space, expansion in healthcare and regulatory frameworks, and favorable reimbursement. Market challenges will include cost and reimbursement issues, safety concerns, and delays in treatment. Lucintel expects that differences in the health needs of the population and progress in research would define the market and product strategy of the competitors. The factors responsible for driving this market include: • Rising Awareness of Hidradenitis Suppurativa: Greater awareness and training of healthcare professionals will enhance the recognition and diagnosis of hidradenitis suppurativa and promote the treatment of less advanced disease. Increased awareness will also lead to an increase in the diagnosis of hidradenitis suppurativa and the treatment of more advanced disease. Hidradenitis suppurativa is often misdiagnosed as other conditions. Over the last few years, many patient support groups and resources have been created to educate the public on hidradenitis suppurativa. Digital resources have further contributed to hidradenitis suppurativa patients’ recognition of their condition and the negative effects of the condition. These resources have also promoted patient advocacy for disease awareness and the development of standardized care. Additionally, many healthcare professionals have reported increased recognition of hidradenitis suppurativa, due in part to the resources created by patient advocacy groups. It is expected that over the next 3-5 years, awareness will continue to increase. • Innovation in Biologics: Despite limitations in our understanding of the ethology of hidradenitis suppurativa (HS), including the interleukins and tumour necrosis factor pathways, several targeted therapies are being developed. We expect that HS therapies will demonstrate “durable” responses. Moreover, we anticipate that many of these therapies will undergo phase 2 or 3 clinical development in the near future. Building on the evidence in support of the above hypotheses, industry experts expect that many novel biologics will enter the market in the next 3-5 years. • Rising Patient Expectations: HS is a disabling and socially stigmatizing condition that causes Olfactory Embarrassment™ (Offensive Odor) and significantly limits patient social activities. As a result, patients have a strong desire for the availability of long-lasting and (ideally) curative therapies. In 2025, it was anticipated that many patients would be unwilling to tolerate (or receive reimbursement for) short-term (and potentially inadequate) therapies, e.g., antibiotics. In 2025, there was a strong expectation among patient advocacy groups that continuously improving therapies will achieve therapeutic remission and enhance patients’ quality of life. Accordingly, it is expected that, in the next 3-5 years, many pharmaceutical companies will modify their products and/or products-in-development to fulfil this expectation. • Improved Infrastructure for Diagnosis and Care: Extended dermatology services, Teledermatology, and electronic referral systems enable improved access to specialist care. Other pathways have been developed to bring different professionals including surgeons, pain management specialists, psychologists and therapists together to provide integrated care to patients. In 2025, telehealth services provided consultation by dermatologists to patients living in high need, hard to reach areas of the region. In the coming years it is expected that ongoing improvements to the telehealth and connectivity infrastructure will close the geographic divides in the access to specialty dermatology care and enable equitable access to specialized therapies. • Regulatory and Pipeline Development: The increasing number of clinical trials and FDA approvals reflect growing interest by pharmaceutical companies in developing innovations and investments in hidradenitis suppurativa. Other inflammatory skin conditions also benefit from improved standards and procedures used by regulatory agencies to evaluate pharmaceutical innovations. Improved standards, safety and effectiveness of pharmaceutical products are expected in the next three to five years, especially in the areas of inflammatory skin conditions. The challenges facing this market include: • High Costs of Treatment: Biologics come with a high price tag and increase the financial burden on the patient and the healthcare system. Unlike other conditions where treatment may be short-term and epidemic in nature, hidradenitis suppurativa is a chronic condition and the financial burden of treatment is constantly growing. Incomplete efficacy of treatment causes payers to evaluate the budget impact of treatment in the market. Manufacturers of these biologics may offer patient support programs to offset the financial burden. • Misdiagnosis and Delayed Diagnosis: Because hide’s sigmoidal lesions mimic other conditions, patients may suffer for years prior to an accurate diagnosis. Increasing disease severity and scarring reduces the effectiveness of treatment and make patients less responsive to treatment. Misdiagnosis leads to an inability to recruit patients for clinical trials further stifling research on treatment. In 2025, the development of educational programs for recognition of hidradenitis suppurativa for the medical community was funded to promote early diagnosis. Improving these programs and integrating referral pathways for patients may reduce underdiagnosis. Failure to do so will prevent the true treatment opportunity from being realized. • Safety and Equity: Use of biologic therapies to treat hidradenitis suppurativa carries a risk of serious infections and other side effects and poses challenges with respect to administration and patient adherence. Differences in national reimbursement policies, availability of sub-specialty physicians, and marketing approval result in inequitable access. In the long-term, safety concerns will impact the market potential of biologics for hidradenitis suppurativa. Long-term, the hidradenitis suppurativa treatment market will benefit from improved awareness, targeted biologics, and increased sub-specialty infrastructure. However, high list prices, as well as challenges with safety, access, and equity will continue to impact the market. Companies able to reduce list prices and increase convenience, safety, and accessibility for hidradenitis suppurativa will be successful. The overall market potential will depend on the ability of companies to accelerate and improve the diagnosis and ongoing care of hidradenitis suppurativa patients. List of Hidradenitis Suppurativa Treatment Market Companies Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies hidradenitis suppurativa treatment market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the hidradenitis suppurativa treatment market companies profiled in this report include- • AbbVie • Merck • Pfizer • AstraZeneca • GlaxoSmithKline • Perrigo • Sun Pharma • Almirall • Bausch Health • Johnson & Johnson Hidradenitis Suppurativa Treatment Market by Segment The study includes a forecast for the global hidradenitis suppurativa treatment market by type, application, and region. Hidradenitis Suppurativa Treatment Market by Type [Value ($M) from 2019 to 2035]: • Medications • Surgery • Others Hidradenitis Suppurativa Treatment Market by Application [Value ($M) from 2019 to 2035]: • Hospitals • Clinics • Others Hidradenitis Suppurativa Treatment Market by Region [Value ($M) from 2019 to 2035]: • North America • Europe • Asia Pacific • The Rest of the World Country Wise Outlook for the Hidradenitis Suppurativa Treatment Market Currently the hidradenitis suppurativa market is focused on clinical trials for biological therapies involving interleukin-17 and other pathways downstream from the established tumour necrosis factor pathways. Regulatory agency decisions concerning these trials, along with related investments in manufacturing, will determine the market in various geographic regions between 2025 and 2027. Our recent market research shows that the market is more competitive. • United States: Recent developments indicate further subcutaneous and systemic biologic clinical trials for hidradenitis suppurativa, as indicated by UCB’s January 2025 announcement to continue their Phase 3 trials of bimekizumab, following FDA approval in December 2024. AbbVie and MoonLake, respectively, also initiated advanced phase clinical trials. The U.S. will likely be the first country to gain access to and commercially develop these treatments in the next several years. • China: In March 2025, China Medical System (CMS) announced partnership with MoonLake to conduct clinical trials of Izokibep (an anti-Interleukin-17A) in China. The deal illustrates CMS’s commitment to shorten the time to commercially offer innovative biologics in China. • Germany: The multinational sponsors operating in Germany in February 2025 carried out ongoing studies in dermatology. During the same period, reimbursement policies in Germany mandated health economic assessments of sponsor products to support pricing and reimbursement negotiations. • India: The Indian pharmaceutical industry in April 2025 further liberalized the marketing of biosimilar adalimumab and other biological products of the pharmacology-immunology class. Concurrently, the Indian Dermatology Networks established more comprehensive diagnosis and treatment programs for skin conditions. Reductions in the price of biological products will increase the degree of reimbursement and thus broaden the pool of patients eligible for treatment. • Japan: The PMDA and other Japanese health authorities in May 2025 continued processing applications for biologics. As part of the process, a number of sites throughout Japan, including major tertiary care hospitals, recruited participants in pivotal clinical trials for hidradenitis suppurativa and other similar conditions. As with other countries, progress in Japan toward relevant evidence for PMDA and reimbursement decisions will facilitate the approval of biologics for dermatological indications. Features of the Global Hidradenitis Suppurativa Treatment Market Market Size Estimates: hidradenitis suppurativa treatment market size estimation in terms of value ($B). Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions. Segmentation Analysis: hidradenitis suppurativa treatment market size by type, application, and region in terms of value ($B). Regional Analysis: hidradenitis suppurativa treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World. Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the hidradenitis suppurativa treatment market. Strategic Analysis: This includes M&A, new product development, and competitive landscape of the hidradenitis suppurativa treatment market. Analysis of competitive intensity of the industry based on Porter’s Five Forces model. If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more. This report answers following 11 key questions: Q.1. What are some of the most promising, high-growth opportunities for the hidradenitis suppurativa treatment market by type (medications, surgery, and others), application (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)? Q.2. Which segments will grow at a faster pace and why? Q.3. Which region will grow at a faster pace and why? Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market? Q.5. What are the business risks and competitive threats in this market? Q.6. What are the emerging trends in this market and the reasons behind them? Q.7. What are some of the changing demands of customers in the market? Q.8. What are the new developments in the market? Which companies are leading these developments? Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth? Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution? Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?